文献速递流行病学与生物统计真实世界研究与卫生经济

纳入比较性观察证据进行试验水平替代终点评价:评估无复发生存作为急性髓系白血病移植后患者总生存的替代终点

Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant.
PubMed 文献 · J Clin Epidemiol · 2025-08-16

系统评价纳入6项随机对照试验和14项比较性观察研究,针对成人急性髓系白血病造血干细胞移植后维持治疗患者,采用贝叶斯元分析模型评估无复发生存(RFS)与总生存(OS)的试验水平替代关系,并开发自适应和用户指定两种信息共享方法。仅用随机对照试验数据时替代关系较弱且参数不确定性大;借用比较性观察研究信息后替代关系增强、参数更精确,自适应信息共享模型未提示先验-数据冲突。结论提示移植后患者可能存在RFS-OS替代关系,新方法可减少不确定性。

要点

  • 系统评价纳入6项随机对照试验和14项比较性观察研究,评估成人急性髓系白血病移植后维持治疗的RFS-OS替代关系。
  • 仅用随机对照试验数据时RFS-OS替代关系较弱,参数不确定性大。
  • 借用比较性观察研究信息后替代关系增强、参数更精确,自适应模型未提示先验-数据冲突。

核心结论

  • 作者认为急性髓系白血病造血干细胞移植后患者中可能存在RFS-OS替代关系。
  • 作者提出的从比较性观察研究借用信息的新方法降低了该替代关系的不确定性,缓解了随机对照试验证据基础有限的问题。

研究设计与样本

  • 系统评价纳入报告RFS和OS治疗效应的随机对照试验和比较性观察研究,对象为接受造血干细胞移植后维持治疗的成人急性髓系白血病患者。
  • 共纳入6项随机对照试验和14项比较性观察研究。
  • 采用贝叶斯元分析模型评估RFS-OS替代关系,并开发统计方法以自适应和用户指定两种方式在随机对照试验与比较性观察研究之间共享信息。

主要发现

  • 仅分析随机对照试验数据时得到较弱的替代关系,参数不确定性大。
  • 以自适应和用户控制两种方式从比较性观察研究借用信息后,RFS-OS替代关系增强且参数更精确。
  • 自适应信息共享模型未提示随机对照试验与比较性观察研究之间存在先验-数据冲突。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Overall survival (OS) is the gold standard outcome for the assessment of treatment benefits in oncology trials. However, OS requires lengthy patient follow-up and can be confounded by competing risks. This study aims to assess the validity of relapse-free survival (RFS) as a trial-level surrogate end point for OS in acute myeloid leukemia (AML) and develop novel methods to combine data from randomized controlled trials (RCTs) and comparative observational evidence (COE) studies. STUDY DESIGN AND SETTING: A systematic review was conducted to identify RCTs and COE studies reporting treatment effects on both RFS and OS in adult patients with AML receiving posthematopoietic stem-cell transplant (HSCT) maintenance therapy. Bayesian meta-analytic models were used to evaluate the RFS-OS surrogate relationship, and statistical methods were developed to enable information sharing, in both adaptive and user-specified manners, between RCTs and COE studies. RESULTS: Six RCTs and 14 COE studies were identified. Analysis of RCT data resulted in a weaker surrogate relationship, with parameters obtained with considerable uncertainty. Borrowing strength from COE studies, in both an adaptive and a user-controlled fashion, resulted in a stronger RFS-OS surrogate relationship with more precise parameters, and adaptive information-sharing models did not suggest any prior-data conflict between the RCTs and COE studies. CONCLUSION: We present evidence for a potential RFS-OS surrogate relationship in patients with AML post-HSCT. Our novel methodology for borrowing information from COE studies reduced uncertainty in this surrogate relationship, alleviating the issue of a limited RCT evidence base.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Nikolaidis GF, Tasoulas A, Gourgioti G, et al. Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant. J Clin Epidemiol. 2025. PMID: 40825512. doi:10.1016/j.jclinepi.2025.111933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。